Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Last trade$1.24
Day change-$0.04 (-3.13%)
Day range$1.20 – $1.48
Volume85,543
Market cap$11M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.72M
Price / earnings
—
Price / book
1.34×
Price / sales
5.43×
EV / sales
-4.62×
EV / EBITDA
0.51×
Profitability
Earnings per share
-$1.51
Return on assets
-36.07%
Return on equity
-158.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.51×
Current ratio
8.67×
Quick ratio
6.95×
Cash ratio
6.64×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$17.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FEMY, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$404.6K
$331.83K
$424.89K
$813.39K
$729.39K
$409.27K
$341.26K
$581.58K
Cost of revenue
$187.5K
$142.44K
$158.61K
$303.13K
$293.84K
$158.17K
$117.27K
$192.41K
Gross profit
$217.1K
$189.39K
$266.28K
$510.26K
$435.56K
$251.1K
$224K
$389.17K
Selling, general and administrative
$2.65M
$3.23M
$3.1M
$3.24M
$2.62M
$2.6M
$2.63M
$2.86M
Research and development
$1.94M
$1.95M
$1.31M
$1.81M
$1.38M
$1.41M
$2.97M
$2.17M
Total operating expenses
$4.67M
$5.26M
$4.49M
$5.13M
$4.09M
$4.1M
$5.68M
$5.11M
Operating income
-$4.45M
-$5.07M
-$4.22M
-$4.62M
-$3.65M
-$3.85M
-$5.46M
-$4.72M
Interest expense
-$200.42K
-$186.05K
-$176.61K
-$408.1K
-$532.07K
-$491.5K
-$459.45K
-$440.42K
Income before taxes
-$4.56M
-$4.47M
$846.1K
-$3.94M
-$4.19M
-$4.59M
-$5.9M
-$5.11M
Income taxes
$0
$865
$0
$5.49K
$0
$0
-$4.19K
$10.19K
Net income
-$4.56M
-$4.47M
$846.1K
-$3.95M
-$4.19M
-$4.59M
-$5.9M
-$5.12M
Net income attributable to common shareholders
-$4.56M
-$4.47M
$328.65K
-$3.95M
-$4.19M
-$4.59M
-$5.9M
-$5.12M
EBITDA
-$4.37M
-$4.98M
-$4.14M
-$4.54M
-$3.57M
-$3.77M
-$5.38M
-$4.64M
Basic earnings per share
-$0.53
-$1.33
$0.00
-$1.25
-$2.05
-$3.18
-$4.60
-$4.49
Diluted earnings per share
-$0.53
-$1.33
$0.00
-$1.25
-$2.05
-$3.18
-$4.60
-$4.49
Recent news
Company coverage with links to the original publishers.
Femasys Inc. announced a partnership with SandsRx Pharmacy, the first in a planned network of specialty pharmacy partnerships, to provide medication coordination and preferred pricing for OB/GYN practices offering FemaSeed fertility treatment. The partnership aims to support the integration of Femasys' fertility portfolio into primary care settings, making fertility treatment more accessible and affordable.
Femasys Inc. announced it has doubled the number of actively enrolling sites in its FemBloc FINALE Pivotal Trial to twelve across the United States, including prominent academic centers like Baylor Research Institute and Columbia University Medical Center. The expansion, enabled by August 2026 financing, demonstrates progress in the company's U.S. regulatory strategy for FDA approval of FemBloc, a non-surgical permanent birth control solution already approved in Europe, UK, and New Zealand.
Femasys Inc. (NASDAQ: FEMY) announced CE Mark approval for its FemHSG™ Catheter, designed to support fertility diagnosis procedures when used with the FemVue device. The approval expands the company's fertility portfolio in Europe through commercial partners. The catheter features a small-profile design to accommodate varying uterine cavity sizes and enables comprehensive ultrasound-based diagnostic assessment of the uterine cavity and fallopian tubes.
Femasys Inc. announced a partnership with Refuah Health Center to expand access to FemaSeed, its intratubal insemination product, as a first-line infertility treatment in community-based care settings. The partnership aims to strengthen Femasys' commercial footprint and accelerate adoption of FemaSeed, which has demonstrated over double the pregnancy rates of traditional IUI in clinical trials.
Femasys will showcase its FemaSeed Intratubal Insemination technology at the ASRM 2025 Scientific Congress, highlighting a fertility solution that offers higher pregnancy rates compared to traditional intrauterine insemination (IUI).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.